[1] Wang F S, Fan J G, Zhang Z, et al. The global burden of liver disease: the major impact of China[J]. Hepatology,2014,60(6):2099-2108.
[2] Fujisaka S, Watanabe Y, Tobe K. The gut microbiome: a core regulator of metabolism[J]. J Endocrinol,2023,256(3):1-21.
[3] 张静雯,王玉平,周永宁. 肠道菌群在非酒精性和脂肪性肝病中的作用[J].胃肠病学和肝病学杂志,2017,26(4):468-471.
[4] Lee N Y, Suk K T. The role of the gut microbiome in live cirrhosis treatment[J].Int J Mol Sci,2020,22(1):199-214.
[5] 池 欣,孙 秀,许艺凡,等. 酒精性脂肪性肝病患者肠道菌群特征及其临床意义[J]. 中国肝脏病杂志(电子版),2023,15(1):19-27.
[6] 王玉栎,刘 畅,牛 辰,等. 肠道菌群影响非酒精性脂肪性肝病的机制及应对策略[J]. 微生物与感染,2021,16(5):347-355.
[7] Meroni M, Longo M, Dongiovanni P. The role of probiotics in nonalcoholic fatty liver disease:a new insight into therapeutic strategies[J]. Nutrients,2019,11(11):2642-2656.
[8] Ye J, Pan Q, Shang Y, et al. Core 2 mucin-type O-glycan inhibits EPEC or EHEC O157:H7 invasion into HT-29 epithelial cell[J]. Gut Pathog,2015,7(1):1-9.
[9] Wrzosek L, Miquel S, Noordine M L, et al. Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent[J].BMC Biol,2012,11(1):1-13.
[10] Knight D J, Girling K J. Gut flora in health and disease[J]. Lancet,2003,361(9356):512-519.
[11] Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of clostridia strains from the human microbiota[J]. Nature,2013, 500(7461):232-236.
[12] Tripathi A, Debelius J, Brenner D A, et al. The gut-liver axis and the intersection with the microbiome[J]. Nat Rev Gastroenterol Hepatol,2018, 15(7):397-411.
[13] Ohtani N, Kawada N. Role of the gut-liver axis in the lver inflammation,fibrosis and cancer:a special focus on the gut microbiota relationship[J]. Hepatol Commun,2019, 3(4):456-470.
[14] Riazi K, Azhari H, Charette J H,et al. The prevaalence and incidence of NAFLD worldwide:a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2022, 7(9):851-861.
[15] Tilg H, Adolph T E, Moschen A R. Multiple parallel hypothesis in nonslcoholic fatty liver disease: revisited after a decade[J]. Hepatology,2021, 73(2):833-842.
[16] Chen D, Le T H, Shahidipour H, et al.The role of gut-derived microbial antigens on liver fibrosis initiation and progression[J]. Cell,2019, 8(11):1324-1344.
[17] Lechner S, Yee M, Limketkai B N, et al. Fecal microbiota transplantation for chronic liver disease:current understanding and future direction[J]. Dig Dis Sci,2020,65(3):897-905.
[18] Arab J P, Arress M, Shah V H. Gut microbiota in nonalcoholic fatty liver disease and alcohol-related liver disease: current concepts and perspectives[J]. Hepatol Res, 2020,50(4):407-418.
[19] Qin X, Chen M Y, He B H. Role of short-chain fatty acids in non-alcoholic fatty liver disease and potential therapeutic targets[J]. Front Microbiol, 2025,2025(4):1-9.
[20] Jiao N, Baker S S, Chapa R A, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD[J]. Gut,2018,67(10):1881-1891.
[21] Sharma S, Tiwari N, Tanwar S S. The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis[J]. Naunyn Schmiedebergs Arch Pharmacol,2025,398(9):11541-11579.
[22] Nie Q X, Luo X, Wang K, et al. Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway[J]. Cell,2024,187(11):2717-2734.
[23] Mohammadi Z, Poustchi H, Motamed G N, et al. Fecal microbiota in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: a systematic review[J]. Arch Iran Med,2020,23(1):44-52.
[24] Mohammad M, Dana G,Mohammad A. Gut microbiota dysbiosis contributes to choline unavailability and NAFLD development[J].J Diabetes Metab Disord,2025,24(1):37-42.
[25] Pappo I, Vraje D, Manohar T, et al. Role of probiotics in the treatment of nonalcoholic fatty liverdisease: a Meta-analysis[J]. Euroasian J Hepatogastroenterol,2017,7(2):130-137.
[26] Wu H Y,Chen J J,Guo S Y, et al. Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease[J]. Gut Microbes,2025, 17(1):1-34.
[27] Wang W, Xu A L, Li Z C, et al. Combination of probiotics and salvia miltiorrhiza polysaccharide alleviates hepatic steatosis via gut microbiota modulation and insulin resistance improvement in high fat-induced NAFLD mice[J]. Diabetes Metab J,2020,44(2):336-348.
[28] Kong L, Chen J, Ji X, et al. Alcoholic fatty liver disease inhibited the co-expression of Fmo5 and PPARα to activate the NF-Κb signaling pathway,thereby reducing liver injury via inducing gut microbiota disturbance[J]. J Exp Clin Cancer Res, 2021,40(1):1-18.
[29] Seo B, Jeon K, Moon S, et al. Roseburia spp abundance associates with alcohol consumption in humans and its administration ameliorates alcoholic fatty liver in mice[J].Cell Host Microbe,2020,27(1):25-40.
[30] Plaza D J, Solis U P, Rodriguez R F, et al. The gut barrier,intestinal microbiota, and liver disease:molecularmechanism and strategies to manage[J].Int J Mol Sci,2020,21(21):8351-8363.
[31] Zhang T, Li J, Liu C P, et al. Butyrate ameliorates alcoholic fatty liver disease via reducing endotoxemia an inhibiting liver gasdermin D-mediated pyroptosis[J]. Ann Transl Med,2021,9(10):873-883.
[32] Mullish B H, Thursz M R. Alcohol-associated liver disease: emerging therapeutic strategies[J].Hepatology,2024,80(6):1372-1389.
[33] 李 莹,侯俊杰,王 欣,等. 肠道菌群与脂肪性肝病研究新进展[J]. 世界华人消化杂志,2021,302(9):G966-G978.
[34] Zhang X, Zhivaki C, Blumberg R S. Inflammation in alcoholic liver disease: the role of the gut[J]. Annu Rev Pathol-mech,2020,15: 339-368.
[35] Addolorate G, Ponziani F R, Dionisi T, et al. Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liverd disease[J].Liver Int,2020,40(4):878-888.
[36] Bajaj J S. Alcohol, liver disease and the gut microbiota[J].Nat Rev Gasteoenterol Hepatol,2019,16(4):235-245.
[37] Bajaj J S, Heuman D M, Hylemon A, et al. Altered profile of human gut microbiome is associated with cirrhosis and its comlication[J]. J Hepatol,2014,60(5):940-947.
[38] Therrien A, Bouchard S, Sidani S, et al. Prevalence of small intestinal bacterial overgrowth among chronic pancreatitis patient:a case-control study[J]. Can J Gastroenterol Hepatol,2016,2016(1):1-8.
[39] 郑荣寿,陈 茹,韩冰峰,等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志,2024,46(3):221-231.
[40] Sung H, Ferlay J, Siecel R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwild for 36 cancer in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
[41] Mahmoud Z,Muhammad A E,Aamira T, et al. Sirtuins and gut microbiota: dynamics in health and a journey from metabolic dysfunction to hepatocellular carcinoma[J]. Cells,2025,14(6):1-30.
[42] Behary J, Raposo A E, Amorim N, et al. Defining the temporal evolution of gut dysbiosis and inflammatory responses leading to hepatocellular carcinoma in Mdr2-/-mouse model[J]. BMC Microbiol,2021,21(1):113-127.
[43] Liu W T, Jing Y Y, Gao L, et al. Lipopolysaccharide induces the differentiation of hepatic progenitor cells into myofibroblasts constitutes the hepatocarcinogenesis-associated microenvironment[J]. Cell Death Differ,2020,27(1):85-101.
[44] Nguyen P T, Kanno K, Pham Q T, et al. Senescent hepatic stellate cells caused by deoxycholic acid modulates malignant behavior of hepatocellular carcinoma[J]. J Cancer Res Clin Oncol,2020,146(12):3255-3268.
[45] 葛均波,徐永健,王 辰,等. 内科学[M].9版.北京:人民卫生出版社,2022:395-399.
[46] Zhou S M, Liu M, Zhou L, et al. Preliminary study on abundance and diversity of microbiota in liver tissues of patients with autoimmune liver disease[J]. Chin J Dig, 2019,39(4):244-250.
[47] Shama S, Liu W. Omiga-3 fatty acids and gut microbiota, areciprocal interaction in nonalcoholicfattyliver disease[J]. Dig Dis Sci, 2020,65(3):906-910.
[48] He B, Hoang T K, Tian X, et al. The role of short-chain fatty acids in autoimmune diseases: a comprehensive review[J]. Front Immunol,2019, 10:421-436.
[49] Torres J, Palmela C, Brito H, et al. The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease[J]. United Eur Gastroenterol, 2018,6(1):112-122.
[50] 李变玲,黄会芳. 自身免疫性肝病与肠道菌群失调的研究进展[J]. 胃肠病学和肝病学杂志,2020,29(6):704-707.